5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial
Lucia Del Mastro(Ospedale Policlinico San Martino), Paolo Bruzzi(Alleanza Contro il Cancro), Alessia Levaggi(Azienda Ospedaliera S.Maria), Claudia Bighin(Azienda Ospedaliera S.Maria), Giovanna Cavazzini(University of Padua), Margherita Piras, PierFranco Conte(University of Padua), P. Pronzato(Accademia Nazionale dei Lincei), Elisabetta Landucci(Azienda Ospedaliera Universitaria Pisana), Loredana Miglietta(Ospedale Policlinico San Martino), Valeria Accortanzo, Andrea Michelotti(University of Pisa), Saverio Danese(Ospedale Sant'Anna), Federico Castiglione(Azienda Sanitaria Locale CN2), Francesca Adami(Azienda Ospedaliera Carlo Poma), Tiziana Scotto(Azienda Ospedaliero Universitaria di Sassari), Antonio Durando(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Simona Pastorino(Ospedale Policlinico San Martino), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo)
Cited by 16
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830